Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

Jason Luke, MD
Published: Friday, Nov 20, 2015



Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker of response for immunotherapy in melanoma.

Taking a broad look at the tumor microenvironment via gene expression profiling can provide insight into which patients with melanoma may respond better from immunotherapy, says Luke. Patients who have a T-cell inflamed tumor microenvironment are much more immunotherapy responsive, while patients who have no lymphocytes in their tumor microenvironment will most likely not respond to immunotherapy.

A useful clinical grade test could identify patients who are the most highly inflamed and are therefore good candidates for anti-PD-1 antibodies alone, says Luke. It could also identify those who have inflammation in the tumor microenvironment, and perhaps need the upfront combination of anti-CTLA-4 and PD-1 blocking agents, he adds.

<<< View more from the 2015 SMR Congress



Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker of response for immunotherapy in melanoma.

Taking a broad look at the tumor microenvironment via gene expression profiling can provide insight into which patients with melanoma may respond better from immunotherapy, says Luke. Patients who have a T-cell inflamed tumor microenvironment are much more immunotherapy responsive, while patients who have no lymphocytes in their tumor microenvironment will most likely not respond to immunotherapy.

A useful clinical grade test could identify patients who are the most highly inflamed and are therefore good candidates for anti-PD-1 antibodies alone, says Luke. It could also identify those who have inflammation in the tumor microenvironment, and perhaps need the upfront combination of anti-CTLA-4 and PD-1 blocking agents, he adds.

<<< View more from the 2015 SMR Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x